Factor Associated with Seizure Control in Patients with Acute Seizure Treated by Intravenous Generic Levetiracetam
Tarnthip Hutthawanichakornkul¹, Nanthaphan Chainirun¹,², Kittisak Sawanyawisuth³, Somsak Tiamkao²,³
Affiliation : ¹ Department of Pharmacy, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand ² Integrated Epilepsy Research Group, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand ³ Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
Objective: To evaluate if any of co-morbid diseases is a predictor for seizure controlled in patients with acute seizures treated with intravenous generic levetiracetam.
Materials and Methods: The inclusion criteria were admitted patients who received intravenous generic levetiracetam treatment for seizure control. The primary outcome of the study was seizure control which was defined by no evidence of seizure within 24 hours after intravenous generic levetiracetam treatment.
Results: During the study period, there were 93 patients received intravenous generic levetiracetam. Of those, 14 patients (15.05%) had uncontrolled seizures. There were 19 patients (20.43%) with status epilepticus. Only presence of brain tumor was associated significantly with uncontrolled seizures with an adjusted odds ratio of 5.30 (95% confidence interval of 1.31, 21.40).
Conclusion: The seizure-uncontrolled rate in patients with acute seizure events by the intravenous generic levetiracetam was 15.05%. The significant predictor for seizure uncontrolled was presence of brain tumor.
Received 27 February 2024 | Revised 13 June 2024 | Accepted 20 June 2024
DOI: 10.35755/jmedassocthai.2024.S01.S50-S54
Keywords : Hypertension; Diabetes; Cerebrovascular diseases; Folic acid Status epilepticus; Seizure controlled; Adverse reaction
All Articles
Download